



## **Appendix 4C – Quarterly Cash Flow Report**

**18 October 2017 - Melbourne, Australia.** Sienna Cancer Diagnostics Ltd (“Sienna” or “the Company”), (ASX:SDX), a commercial stage medical technology company focused on the development and commercialisation of innovative cancer-related tests for the diagnostic pathology market, has today released its Appendix 4C Quarterly Cash Flow report for the quarter ending 30 September 2017.

The cash balance at 30 September was \$4.1 million, with net cash inflow for the quarter totalling \$3.4 million. New capital issued through the Company’s IPO contributed \$4.4 million during the quarter and receipts from product sales were \$243,000.

“We continue to work with our US distribution partner StatLab to target large volume private pathology labs and academic institutions performing urine cytology testing. There are a number of labs undertaking evaluation and technical assessment of our IVD test, which is part of the sales process.” said Matthew Hoskin, CEO of Sienna Cancer Diagnostics.

“Towards the end of the quarter we signed an exclusive distribution agreement for Denmark and Sweden with the company Axlabs A/S, which is a positive step forward in our global rollout strategy.”

- ENDS –

### **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics is an Australian medical technology company with operations in the United States, Europe, and Australia. Sienna’s strengths lie in identifying novel technologies that satisfy an unmet clinical / market need, then developing and commercialising them. The Company has demonstrated the utility of its first product with the help of its global clinical partners. Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as an important biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna’s first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology laboratories in those regions. Diagnostic pathology laboratories may now purchase the product for use as an in-vitro diagnostic test for the presence of hTERT, a component of telomerase.

### **For further information, please contact:**

Matthew Hoskin, CEO  
Sienna Cancer Diagnostics  
mhoskin@siennadiagnostics.com.au  
+61 3 8288 2141

Kyahn Williamson  
WE Buchan  
kwilliamson@we-buchan.com  
+61 3 9866 4722

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Sienna Cancer Diagnostics Limited

**ABN**

74 099 803 460

**Quarter ended ("current quarter")**

30 September 2017

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>			
1.1 Receipts from customers		243	243
1.2 Payments for			
(a) research and development		(36)	(36)
(b) product manufacturing and operating costs			
(c) advertising and marketing		(12)	(12)
(d) leased assets			
(e) staff costs		(414)	(414)
(f) administration and corporate costs		(379)	(379)
1.3 Dividends received (see note 3)			
1.4 Interest received		8	8
1.5 Interest and other costs of finance paid			
1.6 Income taxes paid			
1.7 Government grants and tax incentives			
1.8 Other (provide details if material)			
<b>1.9 Net cash from / (used in) operating activities</b>		<b>(590)</b>	<b>(590)</b>
<b>2. Cash flows from investing activities</b>			
2.1 Payments to acquire:			
(a) property, plant and equipment		(6)	(6)
(b) businesses (see item 10)			
(c) investments			

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	(d) intellectual property		
	(e) other non-current assets		
	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
2.3	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	<b>Net cash from / (used in) investing activities</b>	<b>(6)</b>	<b>(6)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares	4,351	4,351
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(378)	(378)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	<b>Net cash from / (used in) financing activities</b>	<b>3,973</b>	<b>3,973</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	721	721
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(590)	(590)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(6)	(6)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,973	3,973

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>4,098</b>	<b>4,098</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	998	221
5.2	Call deposits	3,100	500
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>4,098</b>	<b>721</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter  
\$A'000**

71

-

Remuneration payments to Non-executive Directors.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter  
\$A'000**

-

-

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements	10	-
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Relates to the corporate credit card facility with the Commonwealth Bank.

9. <b>Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	(218)
9.2 Product manufacturing and operating costs	(20)
9.3 Advertising and marketing	(46)
9.4 Leased assets	-
9.5 Staff costs	(432)
9.6 Administration and corporate costs	(230)
9.7 Other (provide details if material)	(25)
<b>9.8 Total estimated cash outflows</b>	<b>(971)</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: .....  
(Company secretary)

Date: .....18 October 2017.....

Print name: ..Tony Di Pietro.....

### **Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.